First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $3M — +392% growth in a single year.
What Moves the Stock
1TYRA-300 Phase 2 clinical trial data releases - objective response rates (ORR), progression-free survival (PFS), and safety profile versus existing FGFR3 inhibitors in bladder cancer patients
2FDA regulatory milestones - IND clearances for new indications, breakthrough therapy designation potential, or accelerated approval pathway eligibility
3Partnership/licensing announcements with major pharma for co-development or commercialization rights (typical deals: $50-200M upfront + milestones)